Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 19/20 | 0.72 |
| ▸ | KIF23 | Q02241 | 1/20 | 0.72 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.69 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.69 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4376437 | 0.89 | KIF11 (0.78) | KIF11KIF23MAP1LC3BCYP3A4CYP2C19 | |
| SCHEMBL4362643 | 0.87 | KIF11 (0.74) | KIF11KIF23MAP1LC3BCYP3A4CYP2C19 | |
| SCHEMBL4367527 | 0.87 | KIF11 (0.74) | KIF11KIF23MAP1LC3BCYP3A4CYP2C19 | |
| SCHEMBL4365095 | 0.87 | KIF11 (0.74) | KIF11KIF23MAP1LC3BCYP3A4CYP2C19 | |
| SCHEMBL4365032 | 0.87 | KIF11 (0.74) | KIF11KIF23MAP1LC3BCYP3A4CYP2C19 | |
| SCHEMBL4363379 | 0.87 | KIF11 (0.74) | KIF11KIF23MAP1LC3BCYP3A4CYP2C19 | |
| SCHEMBL4364330 | 0.87 | KIF11 (0.74) | KIF11KIF23MAP1LC3BCYP3A4CYP2C19 | |
| SCHEMBL5392779 | 0.87 | KIF11 (0.74) | KIF11KIF23MAP1LC3BCYP3A4CYP2C19 | |
| SCHEMBL4364969 | 0.87 | KIF11 (0.70) | KIF11KIF23MAP1LC3BCYP3A4CYP2C19 | |
| SCHEMBL4362668 | 0.86 | KIF11 (0.73) | KIF11KIF23MAP1LC3BCYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1558589-A4 | COMPOUNDS, COMPOSITIONS, AND METHODS | CYTOKINETICS INC (US) | 2008-01-09 | — | — | EP | disclosed |
| US-7271167-B2 | 2-(Imidazol-1-ylalkyl)-3H-quinazolin-4-one derivatives; mitotic kinesin KSP inhibitors; anticarcinogenic, antiinflammatory, and antiproliferative agents | CYTOKINETICS, INC. (US) | 2007-09-18 | — | — | US | disclosed |
| US-7271167-B2 | 2-(Imidazol-1-ylalkyl)-3H-quinazolin-4-one derivatives; mitotic kinesin KSP inhibitors; anticarcinogenic, antiinflammatory, and antiproliferative agents | CYTOKINETICS, INC. (US) | 2007-09-18 | — | — | US | disclosed |
| US-7271167-B2 | 2-(Imidazol-1-ylalkyl)-3H-quinazolin-4-one derivatives; mitotic kinesin KSP inhibitors; anticarcinogenic, antiinflammatory, and antiproliferative agents | CYTOKINETICS, INC. (US) | 2007-09-18 | — | — | US | disclosed |
| US-20060173007-A1 | Compounds, compositions, and methods | CYTOKINETICS, INC. | 2006-08-03 | — | — | US | disclosed |
| EP-1558589-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | Cytokinetics, Inc. (US) | 2005-08-03 | — | — | EP | disclosed |
| WO-2004032879-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | CYTOKINETICS, INC. (US) | 2004-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060173007-A1 | Compounds, compositions, and methods | ALPP, PCNA, TK2 | KIF11 760/4885KIF23 455/4885MAP1LC3B 1871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.